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Introduction {#s1}
============

Schizophrenia (SCZ) is a severe mental illness that has a population prevalence of 0.4 to 0.8% [@pone.0112745-Saha1]. Individuals with SCZ experience psychosis, poor social functioning, and cognitive impairments. SCZ is a highly heritable disorder encouraging research into the genetic component of the disorder [@pone.0112745-Sullivan1]. Large genome-wide studies have recently suggested that common single nucleotide polymorphisms (SNPs) collectively account for at least 32% of the variance in SCZ liability [@pone.0112745-Purcell1],[@pone.0112745-Ripke1],[@pone.0112745-Ripke2],[@pone.0112745-Lee1]. Rare copy number variants (CNVs) have also been shown to contribute to SCZ risk [@pone.0112745-Walsh1],[@pone.0112745-Consortium1],[@pone.0112745-Stefansson1],[@pone.0112745-Vacic1]. Despite these encouraging advances, many of the genetic components of the disease await identification. Besides inherited variants, new mutations may also contribute to risk.

A sizeable proportion of SCZ patients do not have a family history of the disease and it has been hypothesized that *de novo* variants (DNVs) could account for some of these sporadic cases [@pone.0112745-Yang1]. Several lines of evidence support this hypothesis. Firstly, despite the markedly reduced reproductive rate among SCZ patients, the prevalence of the disorder has remained constant in the general population (0.4--0.8%) [@pone.0112745-Bassett1]. DNVs, which are not subject to negative selection, provide an explanation for risk alleles remaining frequent in the population. Secondly, it has been shown that DNV load correlates with paternal age [@pone.0112745-Kong1], which could explain why older males who have accumulated new mutations are more likely than younger males to father schizophrenic children [@pone.0112745-Malaspina1]. Thirdly, DNVs tend to be more deleterious to gene function than inherited ones because they have not been subjected to evolutionary selection (with the exception of mutations incompatible with life) and are thus disease-prone [@pone.0112745-EyreWalker1]. Consistently, individuals with sporadic SCZ carry significantly more *de novo* CNVs than do controls, whereas individuals with familial SCZ do not [@pone.0112745-Xu1]. However, subsequent studies confirming a higher rate of *de novo* CNVs among individuals with SCZ compared with controls did not reveal a significant difference between individuals with sporadic or familial SCZ [@pone.0112745-Malhotra1],[@pone.0112745-Kirov1].

It has become evident that some fraction of disease alleles may occur as *de novo* events. With recent advances in high-throughput sequencing technologies, one can now identify a considerable fraction of *de novo* variation, including single nucleotide variants (SNVs) and small insertions/deletions (indels), thus increasing the proportion of disease risk that can be explained. Five studies have analyzed the contribution of *de novo* variants in sporadic cases of SCZ [@pone.0112745-Xu2],[@pone.0112745-Girard1],[@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Fromer1]. Collectively, these studies reported a mutation rate of ∼1.5×10^−8^ mutation per base per generation, which is consistent with neutral expectations. Regarding the burden of protein-altering variants, some discrepancies exist among these studies. Indeed, Xu et al. (2011 & 2012) observed that individuals with SCZ exhibited a significantly higher ratio of non-synonymous-to-synonymous SNVs compared with controls, whereas Fromer et al. (2014) did not find any significant enrichment.

Here, we further explored the contribution of DNVs to the etiology of sporadic SCZ by sequencing the exomes of 53 affected individuals and of their healthy parents.

Results {#s2}
=======

Schizophrenia trios {#s2a}
-------------------

Fifty-three individuals with sporadic SCZ (39 males and 14 females) and their unaffected parents were recruited. More than half of the patients had a diagnosis of paranoid schizophrenia (n = 31; 58.4%). The remaining patients had a diagnosis of undifferentiated schizophrenia (n = 6, 11.3%), non-organic schizophrenia (n = 5; 9.4%), disorganized schizophrenia (n = 5, 9.4%), schizoaffective disorder (n = 5, 9.4%), or simple schizophrenia (n = 1; 1.9%). The average age at disease onset was 21.03 years. ([Text S1](#pone.0112745.s009){ref-type="supplementary-material"} and [Table S1](#pone.0112745.s004){ref-type="supplementary-material"}).

Exome sequencing data {#s2b}
---------------------

Exome sequencing was conducted for 159 individuals. On average, 206 (±78 SD) million reads were produced per sample. Of these, 198 (±76 SD) million mapped to the reference genome (hg19). After the removal of duplicate reads, 150 (±51 SD) million reads remained. Among these reads, 113 (±40 SD) million were on-target. These reads represented an average coverage of at least 8× for 95.01% (±4.8 SD) of the coding portion of the RefSeq genes. On average, 24,401 (±1,407 SD) variants were detected per individual. [Table S2](#pone.0112745.s005){ref-type="supplementary-material"} summarizes the exome sequencing results for each individual.

Identification of damaging *de novo* variants {#s2c}
---------------------------------------------

In our cohort of 53 proband-parent trios, we identified 47 exonic and 2 intronic conserved splice site DNVs, which were not previously reported in any public SNP database ([Table 1](#pone-0112745-t001){ref-type="table"}). The observed rate of *de novo* events in the RefSeq protein-coding exons was 0.88, corresponding to an exonic point mutation rate of 1.7×10^−8^, in accord with previous reports [@pone.0112745-Xu3],[@pone.0112745-Sanders1],[@pone.0112745-Neale1],[@pone.0112745-ORoak1],[@pone.0112745-Scally1]. The distribution of the number of DNVs per trio did not differ from the Poisson distribution (Chi-square goodness of fit test: p = 0.42; [Figure S1](#pone.0112745.s001){ref-type="supplementary-material"}). Father\'s age at childbirth had no significant effect on the number of DNVs in the offspring (R^2^ = 0.0113; p = 0.44; [Figure S2A](#pone.0112745.s002){ref-type="supplementary-material"}). However, when we separated the father according to the median age at childbirth, we observed a trend towards more DNVs in the children of the oldest fathers (0.79 and 1.08 DNVs in the offspring of the youngest (19--29 years old) and the oldest (30--52 years old) fathers, respectively; one-tailed Student\'s t-Test; p = 0.097; [Figure S2B](#pone.0112745.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0112745.t001

###### List of the 49 validated *de novo* variants.

![](pone.0112745.t001){#pone-0112745-t001-1}

  Proband_ID        Gene Name     Gene ID      Mutation type   Nucleotide change    AA change    SIFT   PP2     MT
  ---------------- ----------- -------------- --------------- ------------------- ------------- ------ ------ ------
  98708               AHDC1     NM_001029882     missense          c.C1459T          p.R487W     0.00   0.99   0.35
  BUZ_406            C5orf4      NM_032385       missense           c.G893A          p.G298E     0.00   1.00   1.00
  SZP_trio26.P      C9orf172    NM_001080482     missense          c.G2855T          p.C952F     0.00   1.00   0.99
  SP-226              DDX20      NM_007204       missense           c.G163C          p.D55H      0.00   1.00   0.99
  15LE-p              KDM3B      NM_016604       missense          c.C4216T         p.R1406W     0.00   1.00   1.00
  360                 LRRC4      NM_022143       missense           c.C327G          p.N109K     0.00   1.00   0.99
  12JC-p              PSMC2      NM_002803       missense           c.G597T          p.E199D     0.02   0.55   1.00
  98768               QSER1     NM_001076786     missense          c.T4100C         p.I1367T     0.00   0.77   0.07
  SP-227              RGS12      NM_198227       missense           c.G161T          p.R702L     0.08   1.00   1.00
  SP-240            SLC22A23     NM_015482       missense           c.T734G          p.L245R     0.00   1.00   0.99
  6TP-p              TMEM8C     NM_001080483     missense           c.C184T          p.R62C      0.02   1.00   0.02
  2142                USP10      NM_005153       missense          c.C2197T          p.R733W     0.00   1.00   0.99
  98757             FAM189A2    NM_001127608     missense           c.C478T          p.P160S     0.09   1.00   0.70
  2256                CHD5       NM_015557       missense          c.G3943A         p.V1315M     0.07   0.92   0.26
  2150                CILP2      NM_153221       missense          c.G1040A          p.R347Q     0.26   0.41   0.02
  88536               DOT1L      NM_032482       missense          c.G2509A          p.A837T     0.81   0.00   0.09
  SP-245              HPCA       NM_002143       missense           c.G334A          p.G112S     0.13   0.00   1.00
  2262               KDELC2      NM_153705       missense           c.A539G          p.K180R     0.32   0.06   0.00
  SZP_trio27.P      KIAA0430    NM_001184998     missense           c.A340C          p.M114L     0.12   0.47   0.01
  2265                KIF24      NM_194313       missense           c.G865A          p.V289I     0.07   0.46   0.99
  98768                KMO       NM_003679       missense          c.G1381T          p.A461S     0.37   0.00   0.00
  SZP_trio26.P        MYLPF      NM_013292       missense           c.G244A          p.V82I      0.11   0.01   0.99
  400                PITRM1     NM_001242309     missense          c.A2129G          p.K710R     0.46   0.48   0.95
  SZP_trio28.P       SHARPIN     NM_030974       missense           c.T427C          p.S143P     0.17   0.99   0.02
  15LE-p             SLC22A9     NM_080866       missense           c.T427A          p.S143T     0.18   0.02   0.00
  2265                SNX19      NM_014758       missense          c.G2128A          p.E710K     0.22   0.42   0.12
  12JC-p              SYNE1      NM_033071       missense          c.A19898T        p.Q6633L     1.00   0.13   0.03
  2145                TIGD7      NM_033208       missense           c.G48A           p.M16I      0.07   0.18   0.01
  2150               ZNF844     NM_001136501     missense          c.A1559G          p.K520R     1.00   0.01    NA
  18 (3) proband     MAP4K4     NM_001242559     nonsense          c.C1795T          p.R599X                  
  98706               CHRNG      NM_005199       nonsense           c.C511T          p.Q171X                  
  SP-236              EIF3B     NM_001037283    splice site      c.2029-1G\>C                                 
  88185              SETD1A      NM_014712      splice site     c.4582delAG\>-                                
  2148                 FN1       NM_002026      frameshift        c.G277_del       p.A93LfsX26                
  233                 AJUBA      NM_032876      synonymous          c.T852G          p.L284L                  
  SZP_trio28.P        ALG11     NM_001004127    synonymous          c.C306T          p.T102T                  
  404                ANKRD44    NM_001195144    synonymous          c.C882T          p.N294N                  
  2254              ARHGAP11A    NM_014783      synonymous         c.C1746T          p.S582S                  
  403                 ARRB2     NM_001257331    synonymous          c.G483A          p.P161P                  
  TON_078             CELF5      NM_021938      synonymous         c.C1359T          p.S453S                  
  SP-227              FOXO1      NM_002015      synonymous          c.G135C          p.S45S                   
  SP-226             NCKAP5      NM_207363      synonymous         c.C4398G         p.A1466A                  
  360                 NHSL2     NM_001013627    synonymous         c.C2341T          p.L781L                  
  98428              ORMDL1     NM_001128150    synonymous          c.G300A          p.K100K                  
  392                 OXA1L      NM_005015      synonymous          c.C591T          p.G197G                  
  403                PRRC2B      NM_013318      synonymous         c.G5880A         p.P1960P                  
  2142               RALGDS     NM_001042368    synonymous         c.C1446T          p.T482T                  
  SP-236              TIMP2      NM_003255      synonymous          c.C651T          p.I217I                  
  SZP_trio26.P       TMEM55B    NM_001100814    synonymous          c.G300A          p.V100V                  

SIFT  =  Sorting Intolerant from Tolerant algorithm, PP2 =  Polyphen2, MT  =  Mutation Taster. In silico prediction scores shaded in grey are considered as damaging.

In addition, we observed four instances of variant alleles being present at low frequencies, ranging from 14 to 21% of reads, indicative of somatic mosaicism in blood cells. We found one nonsense mutation (p.K854X) in *DSG3* and three missense mutations: p.S1006F in *NLRP11*, p.G1352D in *LRRC7*, and p.R1177C in *CC2D2A*. These 4 events were confirmed by Sanger sequencing, which showed a similar level of allelic imbalance ([Figure S3](#pone.0112745.s003){ref-type="supplementary-material"}). As these post-zygotic mutations were not necessarily present in the brain of the patients, we did not analyze them further.

Among the 49 DNVs, we discovered 15 synonymous and 34 protein-altering DNVs, including 29 missense mutations, 2 nonsense mutations, 2 conserved splice-site mutations, and 1 frameshift insertion/deletion. The non-synonymous-to-synonymous mutation ratio of 2.06 was similar to neutral expectations (2.23) [@pone.0112745-Kryukov1]. We did not observe a significant increase in the relative rate of loss-of-function-to-missense mutations in our cohort when compared to controls from published data sets [@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Sanders1],[@pone.0112745-ORoak1],[@pone.0112745-Iossifov1],[@pone.0112745-Rauch1] (0.17 versus 0.13, respectively; X-squared  = 0.0765, p-value  = 0.78). The transition-to-transversion ratio for coding sequences was 2.61, consistent with neutral expectations [@pone.0112745-Abecasis1]. Thirteen out of 29 missense DNVs were classified as damaging by at least 2 of the 3 prediction algorithms used (SIFT, Polyphen2 and Mutation Taster) ([Table 1](#pone-0112745-t001){ref-type="table"}). Among the nonsense mutations, the first creates a stop codon at residue 599 of the MAP4K4 protein, which would result in a truncation mutant lacking the 617 C-terminal amino acids (1273, R599X). The second nonsense mutation is in codon 171 of the CHRNG gene, which would result in a truncation mutant lacking the 376 C-terminal amino acids (517, Q171X). Concerning the splice site mutations, both affect a conserved "AG" dinucleotide of an acceptor site, one within intron 14 of the EIF3B gene and the other within intron 15 of the SETD1A gene; both are predicted to significantly impact normal splicing ([Table S3](#pone.0112745.s006){ref-type="supplementary-material"}). Finally, the indel variant corresponds to a single-nucleotide deletion in the *FN1* gene, resulting in a frameshift at Ala93 and a premature stop codon after the introduction of 26 amino acids. The *FN1* gene produces multiple protein isoforms, the shortest of which contains 657 amino acids (NM_054034.2). Globally, 36% of the DNVs identified in this study (18 out of 49) were predicted as damaging (missense) or loss-of-function (nonsense, conserved splice site and frameshift variants).

We did not observe genes recurrently mutated in our cohort. However, when data from all available studies (including ours) were combined [@pone.0112745-Xu2],[@pone.0112745-Girard1],[@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Fromer1], 21 genes were found to be recurrently mutated with likely damaging DNVs trios ([Table S4](#pone.0112745.s007){ref-type="supplementary-material"}). Among these 21 genes, 13 were found to carry non-synonymous *de novo* SNVs. We then determined the probability of such *de novo* events occurring in these 13 genes based on each gene-specific mutation rate and the total number of non-synonymous *de novo* SNVs observed across all five datasets (1,020 SCZ trios). The number of DNVs observed in these 13 genes was in agreement with the null expectation ([Table 2](#pone-0112745-t002){ref-type="table"}). As splice-site mutations and indels were not accounted for in the mutability calculation, we did not determine the probability of observing multiple events in genes carrying these types of mutations. This analysis, using data from all available studies, revealed a short list of 21 candidate genes, among which some may be confirmed as true risk genes upon the analysis of additional sporadic cases.

10.1371/journal.pone.0112745.t002

###### Probability of occurrence of the observed number of DNVs in genes recurrently hit by non-synonymous de novo SNVs.

![](pone.0112745.t002){#pone-0112745-t002-2}

  Study               Chr.   Mutation     Gene                  AA substitution                 p-value[\*](#nt102){ref-type="table-fn"}
  ------------------ ------ ---------- ---------- -------------------------------------------- ------------------------------------------
  Gulsuner_2013        22    Missense   CACNA1I                    p.797T\>M                                 6.41 x 10^−3^
  Gulsuner_2013        22    Missense   CACNA1I                    p.1311R\>H                  
  Fromer_2014          5     Missense     CD14                     p.152V\>M                                 2.01 x 10^−4^
  Fromer_2014          5     Missense     CD14                      p.27L\>M                   
  Karayiorgou_2012     1     Missense     DPYD                     p.539G\>R                                  5.8 x 10^−4^
  Karayiorgou_2012     1     Nonsense     DPYD     p.621W\>[\*](#nt102){ref-type="table-fn"}   
  Fromer_2014          X     Missense    HUWE1                     p.4237R\>C                                1.18 x 10^−2^
  Fromer_2014          X     Missense    HUWE1                     p.326A\>G                   
  Gulsuner_2013        4     Nonsense   KIAA1109   p.2439Q\>[\*](#nt102){ref-type="table-fn"}                 9.3 x 10^−3^
  Karayiorgou_2012     4     Missense   KIAA1109                   p.4950Y\>D                  
  Fromer_2014          11    Missense    KIF18A                    p.188V\>I                                  2.7 x 10^−4^
  Fromer_2014          11    Missense    KIF18A                     p.20P\>L                   
  Fromer_2014          1     Missense    LPHN2                     p.372P\>R                                 9.01 x 10^−4^
  Fromer_2014          1     Nonsense    LPHN2     p.803R\>[\*](#nt102){ref-type="table-fn"}   
  Fromer_2014          10    Nonsense    MKI67     p.372R\>[\*](#nt102){ref-type="table-fn"}                 5.01 x 10^−3^
  Gulsuner_2013        10    Nonsense    MKI67     p.857K\>[\*](#nt102){ref-type="table-fn"}   
  Fromer_2014          2     Nonsense     NEB      p.639Y\>[\*](#nt102){ref-type="table-fn"}                  3.2 x 10^−2^
  Gulsuner_2013        2     Missense     NEB                      p.7908T\>M                  
  Fromer_2014          1     Missense    NIPAL3                    p.172V\>M                                  1.3 x 10^−4^
  Fromer_2014          1     Nonsense    NIPAL3    p.398R\>[\*](#nt102){ref-type="table-fn"}   
  This study           4     Missense    RGS12                     p.702R\>L                                 2.06 x 10^−3^
  Karayiorgou_2012     4     Missense    RGS12                     p.1120P\>L                  
  Fromer_2014          15    Missense     RYR3                     p.2205V\>M                                1.32 x 10^−2^
  Fromer_2014          15    Missense     RYR3                     p.4730I\>T                  
  Fromer_2014          17    Missense    STAC2                      p.3E\>K                                  1.71 x 10^−4^
  Karayiorgou_2012     17    Missense    STAC2                     p.110L\>P                   

\*Level of statistical significance after Bonferroni correction was set at 0.05/18.000 = 2.70×10^−6^.

(18,000 =  number of RefSeq genes used).

Functional *in silico* analysis of 375 genes affected by protein-altering *de novo* variants (missense predicted as probably damaging by Polyphen, nonsense, conserved splice site (±2) and frameshift Indels) [@pone.0112745-Girard1],[@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Fromer1] and this study ([Table S5](#pone.0112745.s008){ref-type="supplementary-material"}) revealed a marginally significant enrichment for genes involved in cellular component morphogenesis (GOTERM_BP_FAT Gene Ontology, Benjamini p-value  = 3.1×10^−2^) and genes expressed in brain tissues (TISSUE Expression, Benjamini p-value  = 5.4×10^−8^).

Discussion {#s3}
==========

Similar to other studies [@pone.0112745-Xu2],[@pone.0112745-Girard1],[@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Fromer1], we used whole-exome sequencing to estimate the contribution of protein-altering *de novo* mutations to sporadic SCZ and to identify susceptibility genes. Our study reveals that 34% of the sporadic cases analyzed (18 out of 53 cases) carried a predicted damaging *de novo* variant, and our results provide a list of 18 putative candidate genes. The average number of exonic DNV per proband was 0.88, which corresponds to an exonic point mutation rate of 1.7×10^−8^ per nucleotide per generation. The non-synonymous-to-synonymous and loss-of-function-to-missense ratios did not differ from expectations or from those of controls, suggesting no difference in mutational processes in sporadic cases of schizophrenia. In a recent paper, Kong et al. (2012) reported on the importance of father\'s age on the risk of disease, including SCZ [@pone.0112745-Kong1]. This group convincingly showed that the number of *de novo* mutations in one offspring can be explained by the father\'s age at childbirth. We did not observe any positive correlation between these two variables, probably owing to the limited size of our sample and the range of the fathers\' ages at childbirth ([Figure S2A,B](#pone.0112745.s002){ref-type="supplementary-material"}).

Considering all five of the above-mentioned studies, 1,020 SCZ trios have been sequenced, and 21 genes were found mutated in more than one SCZ-affected individual ([Table S4](#pone.0112745.s007){ref-type="supplementary-material"}). Among these 21 genes, RGS12 was found mutated in this study ([Table 2](#pone-0112745-t002){ref-type="table"}). At this stage, none of these genes can be considered definitive risk genes for SCZ, as the recurrence of DNVs is not significant after genome-wide correction ([Table 2](#pone-0112745-t002){ref-type="table"}). Because the estimated mutation rate for indels is less accurate than for SNVs, we did not calculate the probability of observing such events in *LAMA2*. However, the fact that there are 3 occurrences of probably damaging DNVs in this gene makes it a candidate for SCZ risk. Larger samples size will be required to unequivocally identify true risk variants in specific genes.

Functional *in silico* analysis of 375 genes affected by protein-altering *de novo* variants revealed a significant enrichment in genes expressed in brain tissues and genes involved in cellular component morphogenesis. These preliminary results suggest that genes involved in neuronal morphogenesis could be relevant for the altered neurodevelopmental processes in schizophrenia [@pone.0112745-Robicsek1]. Among the 18 candidate genes identified in our study, *RGS12* has emerged as one of the most interesting candidates in this neurodevelopmental context, as RGS12 is known to coordinate the Ras-dependent signals required for promoting and/or maintaining neuronal differentiation [@pone.0112745-Willard1], a process that is perturbed in schizophrenic patients [@pone.0112745-Robicsek1]. The *RGS12* gene encodes a member of the 'regulator of G protein signaling' (RGS) gene family [@pone.0112745-Kimple1]. In PC12 cells and primary dorsal root ganglion neurons, RGS12 sustains nerve growth factor (NGF)-driven ERK activity and, therefore, neurite outgrowth by scaffolding a complete MAPK cascade, including the NGF-receptor TrkA, activated H-Ras, B-Raf, MEK2, and ERK proteins [@pone.0112745-Willard1]. In addition, RGS12 is observed to be among the most down-regulated proteins in sensory-deprived barrel cortex synapses, suggesting that it may participate in the molecular mechanisms of sensory development [@pone.0112745-Butko1].

Methods and Materials {#s4}
=====================

Schizophrenia trios {#s4a}
-------------------

The schizophrenia trios (case and healthy parents) were collected at 5 different psychiatric hospitals ([Text S1](#pone.0112745.s009){ref-type="supplementary-material"}). In each of the families selected, the proband had a diagnosis of schizophrenia, schizoaffective disorder or non-organic psychosis based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Families for which we could not exclude the presence of psychosis, major depression, bipolar disorder, autism, mental retardation, learning and developmental delays, multiple hospitalizations in psychiatric units, or any somatic disorders in first and second-degree relatives were not considered. This research project was approved by the ethics committee of all participating centers (Ethics committee of the University Hospitals of Geneva). All participants or legally authorized representatives provided their written informed consent.

DNA extraction and exome sequencing {#s4b}
-----------------------------------

Genomic DNA extracted from blood was used except for sample SP-226-003 (Mother), whose DNA was extracted from lymphoblastoid cell line. Whole genome amplification was performed on DNA from SP-198-003 (Mother) and 16(1)-Father using the REPLI-g Mini Kit (Qiagen). Exome capture was conducted using the SureSelect Human ALL Exon kits (Agilent Technologies). High-throughput sequencing was performed on a HiSeq2000 (Illumina). Fastq files were processed by our "in-house" pipeline running on the Vital-IT (<http://www.vital-it.ch>) Center for high-performance computing of the Swiss Institute of Bioinformatics (SIB) [@pone.0112745-Santoni1].

Identification of *de novo* variants {#s4c}
------------------------------------

*De novo* variants were identified using VariantMaster [@pone.0112745-Santoni1]. Practically, heterozygous variants detected in the proband with SAMtools and PINDEL quality scores ≥100 and ≥600, respectively were retained for subsequent analysis. These variants were filtered so as to exclude variants with a MAF\>0.01 in dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>), 1000Genomes [@pone.0112745-Abecasis2], and Exome Variant Server (EVS, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: <http://evs.gs.washington.edu/EVS/>)), and variants found within segmental duplications. VariantMaster utilizes the raw (BAM) data to robustly estimate the conditional probability of a variant to be present in the parents. All variants classified as *de novo* by VariantMaster, were subsequently visually inspected using the SAMtools text alignment viewer. Finally, these candidate variants were validated using Sanger sequencing on each family member. The validation rate was at 100% for the SNVs. Most PINDEL calls classified as *de novo* were rejected during visual inspection mainly due to miscalling of indels in homopolymer tracts or trinucleotide repeats.

Statistical analysis {#s4d}
--------------------

The mutation rate (M) of each of the RefSeq gene was calculated by adding up mutation rates of each nucleotide taking into account the mutation rates at CpG and non-CpG sites [@pone.0112745-Kong1].

We used a germline mutation rate of (i) 6.18×10^−8^ per base per generation for transition at non-CpG sites, (ii) 1.12×10^−7^ per base per generation for transition at CpG sites, (iii) 3.76×10^−9^ per base per generation for transversion at CpG site and (iv) 9.59×10^−9^ per base per generation for transversion at CpG sites. Accordingly, the probability of finding a single mutation in a gene G was where (G) is the set of all captured genes. Thus, the probability of finding N mutations out of 667 DNVs (number of non-synonymous DNVs observed across this and previously published studies [@pone.0112745-Xu2],[@pone.0112745-Girard1],[@pone.0112745-Xu3],[@pone.0112745-Gulsuner1],[@pone.0112745-Fromer1] on a specific gene G can be calculated by the binomial distribution: . Independently, we may also evaluate the probability of these N mutations in G to be non-synonymous. For each amino acid , the number of non synonymous mutations can be easily calculated as where is the number of codons coding for the amino acid . Thus, the probability that a mutation in a gene with coding sequence will be non-synonymous is . For each gene, the final P value is calculated as .

Functional In Silico Analysis {#s4e}
-----------------------------

Functional annotation of genes carrying protein-altering *de novo* variants was performed by Gene Ontology analysis, using a modified Fisher\'s exact test with Benjamini correction for multiple testing as implemented in DAVID (<http://david.abcc.ncifcrf.gov/>).
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